SCHEMBL5879310

SCHEMBL5879310

O=C1C=C(c2c[nH]c3ncccc23)C(=O)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.49
KDR P35968 1/20 0.49
CAMKK2 Q96RR4 2/20 0.48
TGFBR1 P36897 3/20 0.48
PDPK1 O15530 2/20 0.48
IKBKE Q14164 2/20 0.48
PIM1 P11309 3/20 0.46
CDC7 O00311 4/20 0.46
CDK2 P24941 2/20 0.46
MAP4K4 O95819 2/20 0.46
PRKACA P17612 2/20 0.46
GSK3B P49841 2/20 0.46
HIPK2 Q9H2X6 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
CDK9 P50750 2/20 0.46
CDK5 Q00535 2/20 0.46
ROCK2 O75116 1/20 0.46
IRAK4 Q9NWZ3 1/20 0.46
CCNT1 O60563 1/20 0.46
CCNA2 P20248 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16705131 0.81 FLT3 (0.67) FLT3KDRCAMKK2TGFBR1PDPK1
SCHEMBL5618155 0.77 TGFBR1 (0.71) FLT3CAMKK2TGFBR1PDPK1IKBKE
SCHEMBL27748684 0.77 CAMKK2 (0.48) FLT3KDRCAMKK2TGFBR1PDPK1
SCHEMBL5879226 0.75 FLT3 (0.57) FLT3KDRCAMKK2TGFBR1PDPK1
SCHEMBL29771997 0.75 PRKCB (0.65) FLT3KDRPIM1CDK2PRKACA
SCHEMBL2193383 0.75 PRKCB (0.65) FLT3KDRPIM1CDK2PRKACA
SCHEMBL28506448 0.74 PTPRC (0.49) CAMKK2TGFBR1PDPK1IKBKEPIM1
SCHEMBL13596802 0.74 PRKCB (0.72) FLT3KDRTGFBR1PDPK1IKBKE
SCHEMBL5879209 0.73 PIM1 (0.49) FLT3KDRCAMKK2TGFBR1PDPK1
SCHEMBL1050911 0.72 TGFBR1 (0.60) FLT3CAMKK2TGFBR1PDPK1IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 FLT3 3152/4885KDR 2824/4885CAMKK2 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.